No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: A meta-analysis of randomized controlled trials
Open accessThe DOI matches its Crossref record; 69 of the 70 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: Statins showed mixed results in heart failure (HF) patients. The benefits in major HF outcomes, including all-cause mortality and sudden cardiac death (SCD), have always been discordant across systematic reviews and meta-analyses. We intended to systematically identify and appraise the available evidence that evaluated the effectiveness of statins in clinical outcomes for HF patients. DESIGN: Systematic review and meta-analysis. DATA SOURCES: We searched, until April 28, 2016: Medline, Embase, ISI Web of Science and EBM reviews (Cochrane DSR, ACP journal club, DARE, CCTR, CMR, HTA, and NHSEED), checked clinicaltrials.gov for ongoing trials and manually searched references of included studies. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: We identified 24 randomized clinical trials that evaluated the efficacy of statins for HF patients. All randomized clinical trials were assessed for risk of bias and pooled together in a meta-analysis. Pre-specified outcomes were sudden cardiac death, all-cause mortality, and hospitalization for worsening heart failure. RESULTS: Statins did not reduce sudden cardiac death (SCD) events in HF patients [relative risk (RR) 0.92, 95% confidence interval (CI) 0.70 to 1.21], all-cause mortality [RR 0.88, 95% CI 0.75 to 1.02] but significantly reduced hospitalization for worsening heart failure (HWHF) although modestly [RR 0.79, 95% CI 0.66 to 0.94]. Nevertheless, estimated predictive intervals were insignificant in SCD, all-cause mortality and HWHF [RR, 0.54 to 1.63, 0.64 to 1.19, and 0.54 to 1.15], respectively. An important finding was the possible presence of publication bias, small-study effects and heterogeneity of the trials conducted in HF patients. CONCLUSIONS: Statins do not reduce sudden cardiac death, all-cause mortality, but may slightly decrease hospitalization for worsening heart failure in HF patients. The evaluation of the risk of biases suggested moderate quality of the published results. Until new evidence is available, this study supports the 2013 ACCF/AHA guidelines to not systematically prescribe statins in "only" HF patients, which should help avoid unnecessary polypharmacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









![Fig 10 Efficacy of statins compared with control in heart failure stratified by endpoint (those with against without mortality and/or HWHF) for the prevention of (A) sudden cardiac death (SCD) (B) all-cause mortality, and (C) hospitalization for worsening heart failure (HWHF). [Random-effects model].](https://figures.cochat.ai/paper-figures/cac0e8a037214453a87b9e1eaa0761a4/no-benefits-of-statins-for-sudden-cardiac-death-prevention-in-patients-with-figure-10.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [450]
Experimental — accuracy not yet measuredIn the citing paper
“Results were consistent in the subgroup of patients with a history of MI (81% of all patients) [119,450].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [450]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“Also, we rated the quality of the evidence using a summary of findings table from the GRADE approach [28].”
Method(2008) · Cited by 3,790
Zipes, D. P., & Wellens, H. J. J. (1998) · Circulation · doi:10.1161/01.cir.98.21.2334 · Cited by 2,744
Rosuvastatin in older patients with systolic heart failure
Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706201 · Cited by 1,487 · cited 10×
“The mean age of the three biggest studies (CORONA [13], GISSI-HF [12] and Takano H.”
BackgroundMethodResultInfluentialChemical, pharmacokinetic and pharmacodynamic properties of statins: an update
Schachter, M. (2005) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2004.00299.x · Cited by 1,211 · cited 1×
“Many argued that CORONA [13] and GISSI-HF [12] used a hydrophilic statin (rosuvastatin) that may have a different effectiveness than the predominantly lipophilic statins (atorvastatin, simvastatin, lovastatin, fluvastatin, cerivastatin and pitavastatin)—pravastatin and rosuvastatin are relatively hydrophilic[62].”
BackgroundGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61240-4 · Cited by 1,106
Sample Size Calculations in Clinical Research
Chow, S.-C., Wang, H., & Shao, J. (2003) · CRC Press eBooks · doi:10.1201/9780203911341 · Cited by 807
The relationship between cholesterol and survival in patients with chronic heart failure
Rauchhaus, M., Clark, A. L., Doehner, W., Davos, C., Bolger, A., Sharma, R., Coats, A. J. S., & Anker, S. D. (2003) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.016 · Cited by 444
Node, K., Fujita, M., Kitakaze, M., Hori, M., & Liao, J. K. (2003) · Circulation · doi:10.1161/01.cir.0000084539.58092.de · Cited by 414 · cited 3×
“et al [50] whereas the authors of those small trials stated that no death occurred during the study period.”
BackgroundInfluential
Research works printed but not linked: 2
- Lipinski MJ, Cauthen CA, Biondi-Zoccai GG, Abbate A, Vrtovec B, Khan BV, et al Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. American Journal of Cardiology. 2009; 104(12): 1708– 16. 10.1016/j.amjcard.2009.07.055 19962481 · DOI
- Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. York (UK): Centre for Reviews and Dissemination; c2014. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure; 2009 [cited 2016 Jun 22]. Available from: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0027479/.
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Delling, F. N., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000757 · Cited by 9,175
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Alonso, A., Beaton, A. Z., Bittencourt, M. S., Boehme, A. K., Buxton, A. E., Carson, A. P., Commodore-Mensah, Y., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001052 · Cited by 5,987
Heart Disease and Stroke Statistics—2021 Update: A Report From the American Heart Association
Virani, S. S., Alonso, A., Aparicio, H. J., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Cheng, S., Delling, F. N., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000950 · Cited by 5,784
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2333 · Cited by 2,171
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., de Ferranti, S. D., et al. (2026) · JACC · doi:10.1016/j.jacc.2025.11.016 · Cited by 304
PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Archives of Medical Science · doi:10.5114/aoms/141941 · Cited by 188
Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O. D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.11.027 · Cited by 178
Writing Committee Members, Blumenthal, R. S., Morris, P. B., Gaudino, M., Johnson, H. M., Anderson, T. S., Bittner, V. A., Blankstein, R., Brewer, L. C., Cho, L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001423 · Cited by 122
Al‐Gobari, M., Al-Aqeel, S., Gueyffier, F., & Burnand, B. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-021108 · Cited by 46
Self-citationFDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later
McGuire, D. K., Marx, N., Johansen, O. E., Inzucchi, S. E., Rosenstock, J., & George, J. T. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13645 · Cited by 42
“With a too high-risk population, although particularly informative for establishing safety, the disease may be too far advanced to allow any demonstration of treatment efficacy because of competing risks, as seen with statins in end-stage kidney disease and heart failure populations.(35,36) The guidance could be more…”
BackgroundBanach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Diagnostyka Laboratoryjna · doi:10.5604/01.3001.0015.4805 · Cited by 36
Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target
Manolis, A. S., Manolis, A. S., Manolis, T. A., & Melita, H. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09804-2 · Cited by 38
Statin Use in Older Adults with Stable Atherosclerotic Cardiovascular Disease
Spencer‐Bonilla, G., Chung, S., Sarraju, A., Heidenreich, P. A., Palaniappan, L. P., & Rodríguez, F. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.16975 · Cited by 26
Choosing statins: a review to guide clinical practice
Borges, R. D. P., Degobi, N. A. H., & Bertoluci, M. C. (2020) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000306 · Cited by 29
“In a meta-analysis of RCTs in patients only with HFrEF, statins modestly reduced hospitalization for worsening hert failure (60), although they did not decrease sudden cardiac death (61).”
BackgroundGouveia, R., MADUREIRA, S., Elias, C., Neves, A., Soares, P. R., Carreira, M., Pereira, J., Ribeiro, A., Amorim, M. J., Almeida, J., et al. (2023) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2023.200197 · Cited by 19
“Nevertheless, statin therapies have not been clearly associated with improved outcomes in HF patients [17,20,24] and LDL-c goals cannot be directly extrapolated to HF patients.”
BackgroundCardiometabolic Dysregulation and Heart Failure
Ashfield, S., & Ojha, U. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm38504 · Cited by 15
“However, concerns have been raised about the generalizability of these trials [46], and subsequent meta-analyses indicated that statin use in HF patients was associated with reductions in all-cause mortality, cardiovascular mortality, and cardiovascular hospitalizations [47,48].”
the I-GrADE Investigators, Rea, F., Calusi, G., Franchi, M., Vetrano, D. L., Roberto, G., Bonassi, S., Kirchmayer, U., Chinellato, A., Bettiol, A., et al. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0600-0 · Cited by 12
Cho, J., Park, I. B., Lee, K., Ahn, T. H., Park, W. B., Kim, J. H., Ahn, Y., Jeong, M. H., & Lee, D. H. (2017) · Journal of Cardiology · doi:10.1016/j.jjcc.2017.10.009 · Cited by 9
Steinberg, B. A., Mulpuru, S. K., Fang, J. C., & Gersh, B. J. (2017) · Heart Rhythm · doi:10.1016/j.hrthm.2017.09.025 · Cited by 9
Babă, D.-F., Suciu, H., Avram, C., Danilesco, A., Moldovan, D.-A., Rauta, R. C., Huma, L., & Sin, I. A. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20043471 · Cited by 7
“In HF patients, statins did not reduce sudden cardiac death events, but was associated with a decreased rate of hospitalization for worsening HF [8].”
BackgroundDavis, J. S., & Sapp, J. L. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000710 · Cited by 7
“There is also no clear evidence that statin therapy [76], anticoagulation, aspirin, or class I antiarrhythmics [13,77] reduce sudden cardiac death.”
BackgroundSystematic review and meta-analysis: a critical examination of the methodology
Martsevich, S. Y., Navasardyan, A. R., Lobastov, K. V., Mikaelyan, M. V., Вячеславовна, М. Е., Suvorov, А. Y., Schastlivtsev, I., Dzhioeva, O. N., Матвеев, В. В., Сергеевна, А. Е., et al. (2023) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2023-2923 · Cited by 7
Bolt, L., Speierer, A., Bétrisey, S., Aeschbacher‐Germann, M., Blum, M. R., Gencer, B., Giovane, C. D., Aujseky, D., Moutzouri, E., & Rodondi, N. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297852 · Cited by 6
“These findings are hypothesis generating and should be further investigated with individual participant data from LLT trials that should be made publicly available [25, 27].”
BackgroundHeart Failure Treatment in 2023: Is There a Place for Lipid Lowering Therapy?
Poloczková, H., & Krejčí, J. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01166-3 · Cited by 5
“The meta-analysis of 24 randomized controlled trials by Al-Gobari concluded that statins did not significantly reduce sudden cardiac death and all causes of mortality but slightly reduce hospitalization for worsening heart failure [29].”
Al‐Gobari, M., Agrinier, N., Soudant, M., Burnand, B., & Thilly, N. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00346-4 · Cited by 4
Self-citationJaiswal, V., Goyal, A., Deb, N., Shama, N., Mittal, V., Rajak, K., Halder, A., Khadka, S., Kumar, T., Ahmed, R., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101311 · Cited by 3
Management of dyslipidemia in special groups
Jayagopal, P. B., & Kerkar, P. G. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.01.018 · Cited by 1
Management of dyslipidaemia in patients with comorbidities—facing the challenge: heart failure
Drexel, H., Frick, M., Zirlik, A., Niessner, A., Huber, K., Tamargo, J., Dobrev, D., MADER, A., & Agewall, S. (2026) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvag033 · Cited by 1
“15,19,20 Accordingly, the current ESC Guidelines state that there is no indication for routine use of lipid-lowering therapy in HF patients without another indication.”
InfluentialLe, H.-H. (2017) · theses.fr (ABES) · doi:10.70675/b5193892z0a0dz4c44za094z0b60132a3758 · Cited by 1
Self-citationЛашкул, Д. А. (2020) · Zaporozhye Medical Journal · doi:10.14739/2310-1210.2020.2.200556
Albuquerque, C. I. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2021.tde-25072021-174251
Lipid-lowering therapy in special situations
Ватутин, Н. Т., Тарадин, Г. Г., Rakitskaya, I. V., Kharchenko, A. V., Stekhina, K. V., Linnik, I. G., Борт, Д. В., Гасендич, Е. С., & Mogilevskaya, K. E. (2021) · Health Food & Biotechnology · doi:10.36107/hfb.2020.i4.s88
Metadata
- Authors
- Al-Gobari, M., Le, H.-H., Fall, M., Gueyffier, F., & Burnand, B.
- Affiliations
- Lyon 1 Université (FR)
- Centre Hospitalier Universitaire Vaudois (CH)
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-02-06
- Volume
- 12
- Issue
- 2
- Pages
- e0171168
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5293250
- OpenAlex
- W2586344441
- Cited by
- 38
- References
- 70
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 2 · 2023: 5 · 2022: 3 · 2021: 8 · 2020: 3 · 2019: 7 · 2018: 2 · 2017: 3
- FWCI
- 0.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Staatssekretariat für Bildung, Forschung und Innovation (2014.0193)
- Ministère de l'Education Nationale, de l'Enseignement Supérieur et de la Recherche
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- statins, heart failure, reduced ejection fraction, sudden cardiac death, all-cause mortality, hospitalization for worsening heart failure, risk of bias, publication bias, small-study effects, trial heterogeneity, cardiovascular risk stratification, secondary prevention, LDL cholesterol lowering, statin tolerability
- MeSH terms
- Cause of Death, Heart Failure, Humans, Stroke Volume, Odds Ratio, Randomized Controlled Trials as Topic, Death, Sudden, Cardiac, Treatment Outcome, Publication Bias, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.